Avadel Pharmaceuticals (STU:AWK) 3-Year EBITDA Growth Rate : 0.00% (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Avadel Pharmaceuticals 3-Year EBITDA Growth Rate?

Avadel Pharmaceuticals's EBITDA per Share for the three months ended in Mar. 2024 was €-0.24.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Avadel Pharmaceuticals was 51.50% per year. The lowest was -128.10% per year. And the median was -3.00% per year.

Competitive Comparison of Avadel Pharmaceuticals's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Avadel Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avadel Pharmaceuticals's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Avadel Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Avadel Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.

Avadel Pharmaceuticals 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Avadel Pharmaceuticals (STU:AWK) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Avadel Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Avadel Pharmaceuticals's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Avadel Pharmaceuticals (STU:AWK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Avadel Pharmaceuticals PLC (STU:AWK) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

AVDL:USA

Address

10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380

Website

https://www.avadel.com

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company markets products in both the primary care and sterile injectables markets. Its products portfolio includes Bloxiverz, Vazculep (phenylephrine hydrochloride injection), Akovaz (ephedrine sulfate injection), Karbinal ER (carbinoxamine maleate extended-release oral suspension), AcipHex Sprinkle (rabeprazole sodium), Cefaclor for Oral Suspension, 125 mg/5 mL, 250 mg/5 mL and 375 mg/5 mL, and Flexichamber. Majority of the revenue is derived from the United States.